MUSC Catalyst News

At just 27-years-old, post-doctoral scholar Cortney Gensemer, Ph.D., has quickly made a name for herself in the genetic research world.

A multicenter study finds that patients with cystic fibrosis can safely take a dual combination of CF modulator drugs for four years.

Using the power of bioinformatics, GI scientists turned cancer researchers find that elevated levels of molecular motor Myo5b are implicated in uterine cancer.

Long-term antibiotic use disrupts the healthy gut microbiome, leading to changes in liver metabolism that promotes abdominal fat accumulation.

MUSC researchers show that AI can be used to help to identify liver cirrhosis in electronic health records.

MUSC team finds an innovative way to reach more patients with clinical trials.

An MUSC Hollings Cancer Center team has created what members believe to be among the first small molecules designed to stimulate immune cells to fight cancer.

Innovative study tests trauma treatment for people with HIV to try to ensure they take medication, stay on healthy track.

An MUSC Hollings Cancer Center doctor is one of only 12 chosen to participate in the National Cancer Institute’s Early-stage Surgeon Scientist Program.

891 riders and 105 teams raised more than $433,000 to make LOWVELO22 the biggest yet.